Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Lenvatinib Neoadjuvant Therapy in High-Risk RCC
NCT06138496Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University. Started Sep 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06138496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138496.